US5559094A
(en)
*
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
BR9607647A
(en)
*
|
1995-03-17 |
1999-04-06 |
Novo Nordisk As |
Insulin derivative and pharmaceutical composition and process for the treatment of diabetes in a patient in need of this treatment
|
US6251856B1
(en)
|
1995-03-17 |
2001-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
DE19726167B4
(en)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, process for its preparation and pharmaceutical preparation containing it
|
US7638618B2
(en)
|
2001-02-20 |
2009-12-29 |
Sanofi-Aventis Deutschland Gmbh |
Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
|
US7202059B2
(en)
|
2001-02-20 |
2007-04-10 |
Sanofi-Aventis Deutschland Gmbh |
Fusion proteins capable of being secreted into a fermentation medium
|
DE10114178A1
(en)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinc-free and low-zinc insulin preparations with improved stability
|
DE10227232A1
(en)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Sour insulin preparations with improved stability
|
ES2397241T3
(en)
|
2004-01-21 |
2013-03-05 |
Novo Nordisk Health Care Ag |
Conjugation of peptides by transglutaminase
|
ES2542146T3
(en)
|
2006-07-31 |
2015-07-31 |
Novo Nordisk A/S |
PEGylated extended insulin.
|
KR101699370B1
(en)
|
2006-09-22 |
2017-02-14 |
노보 노르디스크 에이/에스 |
Protease resistant insulin analogues
|
CN101674812B
(en)
|
2007-04-30 |
2013-12-11 |
诺沃-诺迪斯克有限公司 |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
DK2229407T3
(en)
|
2008-01-09 |
2017-02-27 |
Sanofi Aventis Deutschland |
NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
|
EP2254905B1
(en)
|
2008-03-14 |
2016-12-14 |
Novo Nordisk A/S |
Protease-stabilized insulin analogues
|
WO2009115469A1
(en)
|
2008-03-18 |
2009-09-24 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
DE102008051834A1
(en)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
|
DE102009038210A1
(en)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
|
WO2010043566A2
(en)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a glp-1 agonist
|
DE102008053048A1
(en)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
|
DE102008064270A1
(en)
*
|
2008-12-20 |
2010-07-01 |
Voith Patent Gmbh |
Flotation method for removing contaminants from aqueous fibrous material suspension by gas bubbles, involves supplying stream of fibrous material suspension along interference body after supplying stream of gas
|
HUE030499T2
(en)
|
2009-07-06 |
2017-05-29 |
Sanofi Aventis Deutschland |
Aqueous preparations comprising methionine
|
EP2451471A1
(en)
|
2009-07-06 |
2012-05-16 |
Sanofi-Aventis Deutschland GmbH |
Slow-acting insulin preparations
|
TW201105346A
(en)
|
2009-07-06 |
2011-02-16 |
Sanofi Aventis Deutschland |
Heat-stable and vibration-stable insulin preparations
|
RU2556340C2
(en)
|
2009-07-31 |
2015-07-10 |
Санофи-Авентис Дойчланд Гмбх |
Long-acting insulin composition
|
PE20120918A1
(en)
|
2009-07-31 |
2012-08-14 |
Sanofi Aventis Deutschland |
DEPTH DRUGS THAT INCLUDE AN INSULIN-CONNECTOR CONJUGATE
|
US9707176B2
(en)
|
2009-11-13 |
2017-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
ES2855146T3
(en)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
CA2802510A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Novo Nordisk A/S |
Insulin derivatives containing additional disulfide bonds
|
US8883722B2
(en)
|
2010-06-23 |
2014-11-11 |
Novo Nordisk A/S |
Human insulin containing additional disulfide bonds
|
WO2011161124A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Novo Nordisk A/S |
Insulin analogues containing additional disulfide bonds
|
PT2611458T
(en)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
WO2012123519A2
(en)
*
|
2011-03-15 |
2012-09-20 |
Novo Nordisk A/S |
Human insulin analogues and derivatives comprising cysteine substitutions
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
PT2750699E
(en)
|
2011-08-29 |
2015-11-03 |
Sanofi Aventis Deutschland |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013153000A2
(en)
|
2012-04-11 |
2013-10-17 |
Novo Nordisk A/S |
Insulin formulations
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
CA2880085C
(en)
|
2012-06-04 |
2021-09-07 |
Diamedica Inc. |
Human tissue kallikrein 1 glycosylation isoforms
|
CN104994864B
(en)
|
2012-12-19 |
2018-05-29 |
沃克哈特有限公司 |
Include actrapid monotard or the stable aqueous composition of its analog or derivative
|
JP2016505601A
(en)
|
2012-12-26 |
2016-02-25 |
ウォックハート リミテッド |
Pharmaceutical composition
|
TWI780236B
(en)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
JP2016531847A
(en)
|
2013-09-30 |
2016-10-13 |
ウォックハート リミテッド |
Pharmaceutical composition
|
AU2014333979B2
(en)
|
2013-10-07 |
2018-02-15 |
Novo Nordisk A/S |
Novel derivative of an insulin analogue
|
CN112957455A
(en)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
WO2016001862A1
(en)
|
2014-07-04 |
2016-01-07 |
Wockhardt Limited |
Extended release formulations of insulins
|
CN107206058A
(en)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
Insulin glargine/lixisenatide fixed ratio preparaton
|
TWI748945B
(en)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
Treatment type 2 diabetes mellitus patients
|
TW201705975A
(en)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
Treatment of type 2 diabetes mellitus patients
|
HUE055231T2
(en)
|
2016-12-16 |
2021-11-29 |
Novo Nordisk As |
Insulin containing pharmaceutical compositions
|
EP3592377A4
(en)
|
2017-03-09 |
2021-02-17 |
Diamedica Inc. |
Dosage forms of tissue kallikrein 1
|
EP3668892A1
(en)
|
2017-08-17 |
2020-06-24 |
Novo Nordisk A/S |
Novel acylated insulin analogues and uses thereof
|
CN109646396A
(en)
*
|
2018-12-29 |
2019-04-19 |
江苏万邦医药科技有限公司 |
A kind of stable insulin analog injection and preparation method thereof
|